CNS Pharmaceuticals (CNSP)
(Delayed Data from NSDQ)
$0.21 USD
0.00 (1.90%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.20 -0.01 (-6.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.21 USD
0.00 (1.90%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.20 -0.01 (-6.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.
5 Beaten-Down Biotech Bets to Bounce Back in 2022
by Indrajit Bandyopadhyay
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Bears are Losing Control Over CNS Pharmaceuticals, Inc. (CNSP), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for CNS Pharmaceuticals, Inc. (CNSP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.